Loading
A phase 1/2 trial of Penpulimab and Gemcitabine in pancreatic ductal adenocarcinoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C is a phase 1/2 interventional study registered as NCT06821503 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 72 participants planned, started 2025-04-11 and due to reach its primary completion in 2027-12. Interventions recorded: LM-108 injection, Penpulimab injection, Paclitaxel for injection (albumin bound) and Gemcitabine hydrochloride for injection.
Shares Penpulimab, Sino Biopharmaceutical (Chia Tai Tianqing), Immune checkpoint inhibitors and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.